Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Chen, Junyi ^a,b   Jiao, Li ^a   Xu, Chuanliang ^a   Yu, Yongwei ^a   Zhang, Zhensheng ^a   Chang, Zheng ^a   Deng, Zhen ^a   Sun, Yinghao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Androgen receptor; Gamma synuclein; Metastasis; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; GAMMA SYNUCLEIN; LUCIFERASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CASTRATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ASSAY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PREDICTION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANDROGENS; ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GAMMA-SYNUCLEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84870672393     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-593     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Ding-wei YE, Chang-ling LI. Epidemiological trends of prostate cancer: retrospect and prospect. China Oncology 2007, 17:1177-1180.
3. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000, 85:60-67. 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B, 10585584.
4. Eckersberger E, Finkelstein J, Sadri H, Margreiter M, Taneja SS, Lepor H, Djavan B. Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. Rev Urol 2009, 11:127-133. 2777060, 19918338.
5. Canfield SE. Annual screening for prostate cancer did not reduce mortality from prostate cancer/Annual screening for prostate cancer did not reduce mortality from prostate cancer. Evid Based Med 2009, 14:104-105. 10.1136/ebm.14.4.104, 19648421.
6. George JM. The synucleins. Genome Biol 2002, 3:3002.1-3002.6.
7. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994, 345:27-32. 10.1016/0014-5793(94)00395-5, 8194594.
8. Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM. γ-synuclein and the progression of cancer. FASEB J 2007, 21:3419-3430. 10.1096/fj.07-8379rev, 17567567.
9. Amer DA, Irvine GB, El-Agnaf OM. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res 2006, 173:223-233. 10.1007/s00221-006-0539-y, 16733698.
10. Bohlen Und HO. Synucleins and their relationship to Parkinson's disease. Cell Tissue Res 2004, 318:163-174. 10.1007/s00441-004-0921-7, 15503152.
11. Wu K, Quan Z, Weng Z, Li F, Zhang Y, Yao X, Chen Y, Budman D, Goldberg ID, Shi YE. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis. Breast Cancer Res Treat 2007, 101:259-267. 10.1007/s10549-006-9296-7, 16821081.
12. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 2000, 88:2154-2163. 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9, 10813729.
13. Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T. Demethylation of the synucleing gene CpGisland in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 2004, 10:2447-2451. 10.1158/1078-0432.CCR-03-0107, 15073123.
14. Zhou CQ, Liu S, Xue LY, Wang YH, Zhu HX, Lu N, Xu NZ. Down-regulation of gamma-synuclein in human esophageal squamous cell carcinoma. World J Gastroenterol 2003, 9:1900-1903.
15. Zhao W, Liu H, Liu W, Wu Y, Chen W, Jiang B, Zhou Y, Xue R, Luo C, Wang L, Jiang JD, Liu J. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol 2006, 28:1081-1088.
16. Hu H, Sun L, Guo C, Liu Q, Zhou Z, Peng L, Pan J, Yu L, Lou J, Yang Z, Zhao P, Ran Y. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res 2009, 15:5485-5493. 10.1158/1078-0432.CCR-08-2491, 19706805.
17. Hibi T, Mori T, Fukuma M, Yamazaki K, Hashiguchi A, Yamada T, Tanabe M, Aiura K, Kawakami T, Ogiwara A, Kosuge T, Kitajima M, Kitagawa Y, Sakamoto M. Synuclein-γ is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin Cancer Res 2009, 15:2864-2871. 10.1158/1078-0432.CCR-08-2946, 19351749.
18. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004, 95:955-961. 10.1111/j.1349-7006.2004.tb03183.x, 15596044.
19. Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 2002, 277:35050-35060. 10.1074/jbc.M201650200, 12121974.
20. Singh VK, Zhou Y, Marsh JA, Uversky VN, Forman-Kay JD, Liu J, Jia Z. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs. Cancer Res 2007, 67:626-633. 10.1158/0008-5472.CAN-06-1820, 17234772.
21. Gupta A, Inaba S, Wong OK, Fang G, Liu J. Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1. Oncogene 2003, 22:7593-7599. 10.1038/sj.onc.1206880, 14576821.
22. Jia T, Liu YE, Liu J, Shi YE. Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res 1999, 59:742-747.
23. Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, Wang L, Zhao W, Jiang JD, Liu J. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 2005, 65:7635-7643.
24. Xu B, Sun Y, Tang G, Xu C, Wang L, Zhang Y, Ji J. Id-1 expression in androgen-dependent prostate cancer is negatively regulated by androgen through androgen receptor. Cancer Lett 2009, 278:220-229. 10.1016/j.canlet.2009.01.007, 19201527.
25. Jiao L, Zhang Y, Hu C, Wang YG, Huang A, He C. Rap1GAP interacts with RET and suppresses GDNF-induced neurite outgrowth. Cell Res 2011, 21:327-337. 10.1038/cr.2010.139, 3193442, 20877310.
26. Shin HJ, Baek KH, Jeon AH, Park MT, Lee SJ, Kang CM, Lee HS, Yoo SH, Chung DH, Sung YC, McKeon F, Lee CW. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 2003, 4:483-497. 10.1016/S1535-6108(03)00302-7, 14706340.
27. Inaba S, Li C, Shi YE, Song DQ, Jiang JD, Liu J. Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells. Breast Cancer Res Treat 2005, 94:25-35. 10.1007/s10549-005-6938-0, 16142440.
28. Jiang Y, Liu YE, Goldberg ID, Shi YE. Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis. Cancer Res 2004, 64:4539-4546. 10.1158/0008-5472.CAN-03-3650, 15231664.
29. Jiang Y, Liu YE, Lu A, Gupta A, Goldberg ID, Liu J, Shi YE. Stimulation of estrogen receptor signaling by gamma synuclein. Cancer Res 2003, 63:3899-3903.
30. Pan ZZ, Bruening W, Godwin AK. Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. Int J Oncol 2006, 29:1201-1205.
31. Surguchov A, Palazzo RE, Surgucheva I. Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction. Cell Motil Cytoskeleton 2001, 49:218-228. 10.1002/cm.1035, 11746666.
32. Surgucheva IG, Sivak JM, Fini ME, Palazzo RE, Surguchov AP. Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells. Arch Biochem Biophys 2003, 410:167-176. 10.1016/S0003-9861(02)00664-1, 12559990.
33. Wu K, Weng Z, Tao Q, Lin G, Wu X, Qian H, Zhang Y, Ding X, Jiang Y, Shi YE. Stage-specific expression of breast cancer-specific gene gamma-synuclein. Cancer Epidemiol Biomarkers Prev 2003, 12:920-925.
34. Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 2004, 3:460-467.
35. Lubahn DB, Joseph DR, Sar M, Tan J, Hiqqs HN, Larson RE, French FS, Wilson EM. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988, 2:1265-1275. 10.1210/mend-2-12-1265, 3216866.
36. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999, 69:307-313. 10.1016/S0960-0760(99)00049-7, 10419007.
37. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Nat Cancer Ins 2001, 93:1687-1697.
38. Culig Z. Androgen receptor cross-talk with cell signaling pathways. Growth Factors 2004, 22:179-184. 10.1080/08977190412331279908, 15518241.
39. Heemers HV, Verhoeven G, Swinnen JV. Androgen Activation of the Sterol Regulatory Element-Binding Protein Pathway: Current Insights. Mol Endocrinol 2006, 20:2265-2277. 10.1210/me.2005-0479, 16455816.
40. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interaction between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007, 67:10455-10465. 10.1158/0008-5472.CAN-07-2057, 17974989.
41. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, Park YM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res 2007, 67:9294-9303. 10.1158/0008-5472.CAN-07-0651, 17909037.
42. Shiota M, Yokomizo A, Masubuchi D, Tada Y, Inokuchi J, Eto M, Uchiumi T, Fujimoto N, Naito S. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate 2010, 72:97-102.
43. Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002, 277:4609-4617. 10.1074/jbc.M108312200, 11673464.
44. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999, 274:8316-8321. 10.1074/jbc.274.12.8316, 10075738.
45. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Fujimoto N, Seki NS. Peroxisome proliferator activated receptor g coactivator-1a interacts with the androgen receptor and promotes prostate cancer cell growth by activating the androgen receptor. Mol Endocrinol 2010, 24:114-127. 10.1210/me.2009-0302, 19884383.
46. Shiota M, Song Y, Yokomizo A, Tada Y, Kuroiwa K, Eto M, Oda Y, Inokuchi J, Uchiumi T, Fujimoto N, Seki N, Naito S. Human heterochromatin protein 1isoform HP1ß enhances androgen receptor activity and is implicated in prostate cancer growth. Endocr Relat Cancer 2010, 17:455-467. 10.1677/ERC-09-0321, 20308360.
47. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000, 27:39-66.
48. Bosland MC. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann N Y Acad Sci 2006, 1089:168-176. 10.1196/annals.1386.040, 2821822, 17261765.
49. Bosland MC. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Prog Clin Biol Res 1996, 394:309-352.
50. Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, Quinn J, Aronow BJ, Abate-Shen C. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1, Pten mutant mice. Cancer Res 2007, 67:9089-9096. 10.1158/0008-5472.CAN-07-2887, 17909013.